CRT 2026

LATE-BREAKING CLINICAL TRIALS | STRUCTURAL I

Moderator(s)

• 

  Michael J. Reardon, MD

  Professor and Allison Family Distinguished Chair of Cardiovascular Research
  Houston Methodist DeBakey Heart & Vascular Center
  Houston, Texas, United States

  Disclosure(s): BSCI: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); High Life: Consulting Fees (e.g., advisory boards) (Ongoing); JValve: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Siemens: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); WL Gore & Associates: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Gregg W. Stone, MD, FACC, MSCAI

  Physician
  Mount Sinai
  New York, New York, United States

  Disclosure(s): Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter, Vascentis: Stock-privately held company (Ongoing); Cardiac Success, Occlutech, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio: Consulting Fees (e.g., advisory boards) (Terminated); Colibri, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Ancora, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Bioventrix, MedHub, Biotyx Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Pulnovo, V-wave and PCORI via Weill Cornell Medical Center.: Grant/Research Support (Ongoing)
• 

  Ron Waksman, MD, MSCAI

  Director, Cardiovascular Research and Advanced Education
  MedStar Washington Hospital Center, MedStar Heart and Vascular Institute
  Washington, District of Columbia, United States

  Disclosure information not submitted.

Panel Discussant(s)

• 

  Danny Dvir, MD

  MD
  SZMC, Israel

  Disclosure information not submitted.
• 

  Howard C. Herrmann, MD, FACC, MSCAI

  John Bryfogle Professor Emeritus of Cardiovascular Medicine
  Perelman School of Medicine at the University of Pennsylvania
  Philadelphia, Pennsylvania, United States

  Disclosure(s): Affluent Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Artedrone: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Caranx: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Mass Medical Society: Editorial Fees (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); MicroInterventional Devices: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing)
• 

  Karen M. Kim, MD

  Associate Professor of Cardiovascular and Thoracic Surgery
  University of Texas Health Austin/Dell Medical School
  Austin, Texas, United States

  Disclosure(s): No financial relationships to disclose
• 

  Chad Kliger, MD

  Director, Valve and Structural Heart Center
  Lenox Hill Heart and Lung Institute, Northwell Health
  New York, NY, United States

  Disclosure information not submitted.
• 

  Thomas E. MacGillivray, MD

  Physician Executive Director and Chair, Cardiac Surgery
  MedStar Health, MedStar Washington Hospital Center
  Washington, District of Columbia, United States

  Disclosure information not submitted.
• 

  Michael J. Mack, MD

  Chair, Cardiovascular Servivce Line
  Heart Hospital Baylor Plano
  Plano, Texas, United States

  Disclosure information not submitted.
• 

  Jeffrey J. Popma, MD

  Chief Scientific Officer
  CRF
  Newton, Massachusetts, United States

  Disclosure(s): Medtronic: CMO ended Nov 2024 (Terminated, November 1, 2024), Stock-publicly held company (excluding mutual/index funds) (Terminated, November 1, 2024)
• 

  Molly Szerlip, MD

  Associate Medical Director, Education & Reserach and Regional Director, Sturctural Heart Progam
  Baylor Scott and White The Heart Hospital Baylor Plano
  Richardson, Texas, United States

  Disclosure(s): Abbott Vascular, Medtronic, Boston Scientific: Advisory Board (Ongoing); Boston Scientific: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); CVI Foundation: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Edward Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); SCAI: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Vinod Thourani, MD, FACC, FACS

  Professor of Surgery, Chairman of Cardiovascular Surgery
  Piedmont Heart Institute
  Atlanta, Georgia, United States

  Disclosure(s): Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Edward Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); JenaValve Technology Inc: Grant/Research Support (Ongoing); Laplace: Grant/Research Support (Ongoing); Trisol: Stock Options [in privately held companies] (Ongoing)